CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insight Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs Chapters

This segment of the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Emerging Drugs

• AUTO3: Autolus

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. The therapy is designed to minimize relapse due to single antigen loss in patients with B cell malignancies and is currently being tested for precursor cell lymphoblastic leukemia-lymphoma in its Phase I/II of clinical trials. The drug has also been designated with orphan drug status for precursor cell lymphoblastic leukemia.

• PCAR019: PersonGen Biotherapeutics

PersonGen’s “breakthrough” therapy PCAR019 is currently being evaluated for the treatment of Acute Lymphoblastic Leukemia. The drug is in its phase I trial and targets the CD-19 which is expressed in most B-malignant tumors especially in the former B cells ALL.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Therapeutic Assessment

This segment of the report provides insights about the different CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia

There are approx. 5+ key companies which are developing the therapies for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia. The companies which have their CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drug candidates in the mid to advanced stage, i.e. Phase I/II include, Autolus and others.

The report covers around 5+ products under different phases of clinical development like

• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Insights

• CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs?
• How many CAR T-Cell Therapy for Acute Lymphoblastic Leukemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Acute Lymphoblastic Leukemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Autolus
• PersonGen Biotherapeutics
• Pepromene Bio, Inc.
• Actinium Pharmaceuticals

Key Products

• AUTO3
• PCAR019
• BAFF-R-CAR-T
• Apamistamab

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/kw2qg0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900